1. Home
  2. NVCR vs PLUS Comparison

NVCR vs PLUS Comparison

Compare NVCR & PLUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • PLUS
  • Stock Information
  • Founded
  • NVCR 2000
  • PLUS 1990
  • Country
  • NVCR Jersey
  • PLUS United States
  • Employees
  • NVCR N/A
  • PLUS N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • PLUS Retail: Computer Software & Peripheral Equipment
  • Sector
  • NVCR Health Care
  • PLUS Technology
  • Exchange
  • NVCR Nasdaq
  • PLUS Nasdaq
  • Market Cap
  • NVCR 1.8B
  • PLUS 2.6B
  • IPO Year
  • NVCR 2015
  • PLUS 1996
  • Fundamental
  • Price
  • NVCR $17.49
  • PLUS $96.76
  • Analyst Decision
  • NVCR Buy
  • PLUS Hold
  • Analyst Count
  • NVCR 5
  • PLUS 1
  • Target Price
  • NVCR $26.60
  • PLUS $90.00
  • AVG Volume (30 Days)
  • NVCR 1.3M
  • PLUS 100.1K
  • Earning Date
  • NVCR 10-30-2024
  • PLUS 11-05-2024
  • Dividend Yield
  • NVCR N/A
  • PLUS N/A
  • EPS Growth
  • NVCR N/A
  • PLUS N/A
  • EPS
  • NVCR N/A
  • PLUS 4.08
  • Revenue
  • NVCR $549,964,000.00
  • PLUS $2,195,665,000.00
  • Revenue This Year
  • NVCR $16.23
  • PLUS $5.69
  • Revenue Next Year
  • NVCR $6.09
  • PLUS $4.68
  • P/E Ratio
  • NVCR N/A
  • PLUS $24.00
  • Revenue Growth
  • NVCR 8.33
  • PLUS 0.56
  • 52 Week Low
  • NVCR $10.87
  • PLUS $53.54
  • 52 Week High
  • NVCR $24.74
  • PLUS $102.99
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 43.24
  • PLUS 52.65
  • Support Level
  • NVCR $15.61
  • PLUS $96.35
  • Resistance Level
  • NVCR $17.31
  • PLUS $99.25
  • Average True Range (ATR)
  • NVCR 1.29
  • PLUS 2.09
  • MACD
  • NVCR 0.05
  • PLUS -0.38
  • Stochastic Oscillator
  • NVCR 11.59
  • PLUS 28.23

About NVCR NovoCure Limited

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About PLUS ePlus inc.

ePlus Inc is a holding company. ePlus through its subsidiaries provides information technology solutions. The company's technology solutions enable organizations to optimize their IT environment and supply chain processes. It also provides consulting, professional and managed services, and complete lifecycle management services including flexible financing solutions. ePlus focuses on selling to medium and large enterprises in the United States and to customers in select international markets including the United Kingdom, the European Union, India, Singapore and Israel.

Share on Social Networks: